Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID-2019 - quadrivalent seasonal influenza combined vaccine - Medigen Vaccine Biologics/Vaxess Technologies

Next Previous
X
Search
Drug Profile

COVID-2019 - quadrivalent seasonal influenza combined vaccine - Medigen Vaccine Biologics/Vaxess Technologies

Alternative Names: Combined COVID-19 and quadrivalent seasonal influenza vaccine; Coronavirus + Influenza Combo Patch Vaccine; Coronavirus and Influenza Combo Patch Vaccine - Medigen Vaccine Biologics/Vaxess Technologies

Latest Information Update: 11 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medigen Vaccine Biologics; Vaxess Technologiess
  • Class COVID-19 vaccines; Influenza virus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections; Influenza virus infections

Most Recent Events

  • 11 Apr 2023 Vaxess Technologies plans to initiate a phase II clinical trial for COVID-2019 infections and Influenza virus infections, in-between H2 of 2023 to H1 of 2024 (Vaxess Technologies pipeline, April 2023)
  • 22 Apr 2021 Vaxess Technologiess plans a phase I trial for COVID-2019 infections and Influenza virus infections (Prevention) in 1H 2022 (Transdermal)
  • 22 Apr 2021 Vaxess Technologies receives a Commercialization Readiness Program (CRP) grant from the National Institute of Allergy and Infectious Diseases (NIAID) for COVID-2019 - quadrivalent seasonal influenza combined vaccine development in COVID-2019 infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top